Publicado sep 29, 2021



PLUMX
Almetrics
 
Dimensions
 

Google Scholar
 
Search GoogleScholar


Juan Carlos Gómez Vega

Maria Isabel Ocampo-Navia

Juan José Botero-Trujillo

Rafael Enrique Fandiño-Hidalgo

Juan Carlos Puentes Vargas

##plugins.themes.bootstrap3.article.details##

Resumen

El retinoblastoma constituye el tumor ocular más prevalente en la infancia, con diversas presentaciones clínicas. Los principales objetivos del tratamiento se enfocan en la supervivencia y la preservación de la visión; sin embargo, el tratamiento debe ser individualizado. Existen diferentes alternativas terapéuticas como la enucleación, quimioterapia sistémica, radioterapia y terapias locales. Dentro de las alternativas más recientes esta la quimioterapia intra-arterial, que permite la administración directa de agentes quimioterapéuticos a patologías malignas intraoculares como el retinoblastoma por medio de la arteria oftálmica. El presente artículo tiene como objetivo realizar una revisión no sistematizada sobre las indicaciones, ventajas, desventajas, técnica, tasas de supervivencia, costos y complicaciones de la quimioterapia intraarterial como tratamiento del retinoblastoma.

Keywords

Retinoblastoma, Chemotherapy, Neoplasms, Eye enucleation, MelphalanRetinoblastoma, Quimioterapia, Neoplasias, Enucleación del ojo, Melfalán

References
1. Alzahem T, Alsarhani W, Albahlal A, Abu Safieh L, Aldahmash S. History and Genetics of Retinoblastoma. In: Retinoblastoma - Past, Present and Future. IntechOpen; 2019.
2. Ulos ART, Gómez-martínez R, Leal CA, Rivera-luna R. Los aspectos epidemiológicos en el retinoblastoma bilateral. Gac Medica Mex. 1995;131(5–6):527–31.
3. De Alba Campomanes BG. Enfermedades de los ojos y de la visión. Tenth Edit. Avery. Enfermedades del recién nacido. Elsevier Espa8#241;a, S.L.U.; 2018. 1550-1554 p.
4. Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, Brisse H-J, Sastre-Garau X, Doz F. Retinoblastoma. EMC - Pediatría. 2014 Mar;49(1):1–9.
5. Tarek N, Herzog CE. Retinoblastoma Neoplasias gonadales y de células germinales. 21th Editi. Nelson. Tratado de pediatría. Elsevier Espa8#241;a, S.L.U.; 2017. 1-50 p.
6. Diez J. Oftalmología pediátrica para todos los días. AEPap. 2015;491–502.
7. Handal E. Diagnóstico diferencial de patología ocular en el infante. Honduras Pediátrica. 1998;19(1):9–10.
8. (SEOM) G de T en CH de la SE de OM. Guía de manejo de retinoblastoma. :1–6.
9. Rodriguez-galindo C, Orbach DB, Vanderveen D. Retinoblastoma. Pediatr Clin N Am. 2015;62:201–23.
10. Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol. 2006;17(3):228–34.
11. Ortiz M V, Dunkel IJ. Retinoblastoma. J Child Neurol. 2015;1–10.
12. Rodriguez-Galindo C, Chantada GL, Haik BG, Wilson MW. Treatment of retinoblastoma: current status and future perspectives. Curr Treat Options Neurol. 2007 Jul;9(4):294–307.
13. Chantada G, Schaiquevich P. Management of Retinoblastoma in Children : Current Status. Pediatr Drugs. 2015;
14. Rao R, Honavar SG. Retinoblastoma. Indian J Pediatr. 2017 Dec;84(12):937–44.
15. Shields CL, Bianciotto CG, Jabbour P, Ramasubramanian A, Lally SE, Griffin GC, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol (Chicago, Ill 1960). 2011 Nov;129(11):1399–406.
16. Muen WJ, Kingston JE, Robertson F, Brew S, Sagoo MS, Reddy MA, et al. Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Ophthalmology [Internet]. 2012 Mar;119(3):611–6. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L51779308
17. Ortiz M V, Dunkel IJ. Retinoblastoma. J Child Neurol. 2016 Feb;31(2):227–36.
18. Shields JA, Parsons H, Shields CL, Giblin ME. The role of cryotherapy in the management of retinoblastoma. Am J Ophthalmol. 1989 Sep;108(3):260–4.
19. Shields CL, Santos MC, Diniz W, Gündüz K, Mercado G, Cater JR, et al. Thermotherapy for retinoblastoma. Arch Ophthalmol (Chicago, Ill 1960). 1999 Jul;117(7):885–93.
20. Shields JA, Shields CL, De Potter P. Photocoagulation of retinoblastoma. Int Ophthalmol Clin. 1993;33(3):95–9.
21. Hicsonmez A, Guney Y, Dirican B, Arslan Y, Atakul T, Uysal H. Challenges and differences in external radiation therapy for retinoblastoma: from standard techniques to new developments. Tumori. 2017;103(5):438–42.
22. Kaliki S, Palkonda VAR. Management of retinoblastoma with extraocular tumour extension. Community eye Heal. 2018;31(101):18–9.
23. Zanaty M, Barros G, Chalouhi N, Starke RM, Manasseh P, Tjoumakaris SI, et al. Update on Intra-Arterial Chemotherapy for Retinoblastoma. Sci World J. 2014;1–6.
24. Shields CL, Manjandavida FP, Lally SE, Pieretti G, Arepalli SA, Caywood EH, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014 Jul;121(7):1453–60.
25. Al Saiegh F, Chalouhi N, Sweid A, Mazza J, Mouchtouris N, Khanna O, et al. Intra-arterial chemotherapy for retinoblastoma via the transradial route: Technique, feasibility, and case series. Clin Neurol Neurosurg. 2020 Jul;194:105824.
26. Shields CL, Lally SE, Leahey AM, Jabbour PM, Caywood EH, Schwendeman R, et al. Targeted retinoblastoma management : when to use intravenous , intra-arterial , periocular , and intravitreal chemotherapy. Curr Opin. 2014;25(5):374–85.
27. Shields CL, Jorge R, Say EAT, Magrath G, Alset A, Caywood E, et al. Unilateral Retinoblastoma Managed With Intravenous Chemotherapy Versus Intra-Arterial Chemotherapy. Outcomes Based on the International Classification of Retinoblastoma. Asia-Pacific J Ophthalmol (Philadelphia, Pa). 2016;5(2):97–103.
28. Shields CL, Shields JA. Review Intra-arterial chemotherapy for retinoblastoma : the beginning of a long journey. Clin Exp Ophthalmol. 2010;2009(November 2009):638–43.
29. CL Shields, EM Fulco, JD Arias, C Alarcon, M Pellegrini, P Rishi, S Kaliki CB and JS. Retinoblastoma frontiers with arterial, periocular, and intravitreal chemotherapy. Eye. 2013;27:253–64.
30. Reese AB, Hyman GA, Jr GRM. Treatment of retinoblastoma by radiation and Triethylenemelamine. Arch Ophthalmol. 1954;53(4):505–13.
31. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol. 2004 Apr;9(2):69–73.
32. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008 Aug;115(8):1398–404, 1404.e1.
33. Jabbour, P; Chalouhi, N; Tjoumakaris, S; Gonzalez, F; Dumont, AS; Chitale, R; Rosenwasser, R; Bianiotto, CG; Shields C. Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma. J Neurosurg Pediatr. 2012;10(September):175–81.
34. Klufas MA, Gobin YP, Marr B, Brodie SE, Dunkel IJ, Abramson DH. Intra-arterial chemotherapy as a treatment for intraocular retinoblastoma: alternatives to direct ophthalmic artery catheterization. Am J Neuroradiol. 2012 Sep;33(8):1608–14.
35. Suzuki S, Yamane T, Mohri M, Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011 Oct;118(10):2081–7.
36. Jolly SS, Yusuf S, Cairns J, Niemelä K, Xavier D, Widimsky P, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011 Apr;377(9775):1409–20.
37. Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol (Chicago, Ill 1960). 2011 Jun;129(6):732–7.
38. Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology. 2010 Aug;117(8):1623–9.
39. Schaiquevich P, Ceciliano A, Millan N, Taich P, Villasante F, Fandino AC, et al. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer. 2013 May;60(5):766–70.
40. Ross G, Lipper EG, Abramson D, Preiser L. The Development of Young Children With Retinoblastoma. Arch Pediatr Adolesc. 2001;155:80–3.
41. Peterson, EC; Elhammady, MS; Quintero-Wolff, S; Murray, TG; Aziz-Sultan M. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. J Neurosurg. 2011;114(June):1603–8.
42. Abramson DH, Marr BP, Dunkel IJ, Brodie S, Zabor EC, Driscoll SJ, et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol. 2012 Apr;96(4):499–502.
43. Thampi S, Hetts SW, Cooke DL, Stewart PJ, Robbins E, Banerjee A, et al. Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution. Vol. 7, Clinical ophthalmology (Auckland, N.Z.). 2013. p. 981–9.
44. Abramson DH, Ellsworth RM, Grumbach N, Sturgis-Buckhout L, Haik BG. Retinoblastoma: correlation between age at diagnosis and survival. J Pediatr Ophthalmol Strabismus. 1986;23(4):174–7.
45. Abramson DH, Shields CL, Munier FL, Chantada GL. Treatment of Retinoblastoma in 2015: Agreement and Disagreement. JAMA Ophthalmol. 2015 Nov;133(11):1341–7.
46. Lim, LA; Dalvin, LA; Ancona-Lezama, D; Yu, MD; Jabbour, P, Shields C. Retinoblastoma vascular perfusion and intra-arterial chemotherapy cycle requirements. Clin Experiment Ophthalmol. 2019;1–9.
47. Ravindran K, Dalvin LA, Pulido JS, Brinjikji W. Intra-arterial chemotherapy for retinoblastoma: an updated systematic review and meta-analysis. J Neurointerv Surg. 2019;11:1266–72.
48. Tse BC, Steinle JJ, Johnson D, Haik BG, Wilson MW. Superselective intraophthalmic artery chemotherapy in a nonhuman primate model: histopathologic findings. JAMA Ophthalmol. 2013 Jul;131(7):903–11.
49. Ancona-Lezama D, Dalvin LA, Lucio-Alvarez JA, Jabbour P, Shields CL. OPHTHALMIC VASCULAR EVENTS AFTER INTRA-ARTERIAL CHEMOTHERAPY FOR RETINOBLASTOMA: Real-World Comparison Between Primary and Secondary Treatments. Retina. 2019 Dec;39(12):2264–72.
50. Eagle, RC; Shields, C; Bianciotto, C; Jabbour, P; Shields J. Histopathologic Observations After Intra-arterial Chemotherapy for Retinoblastoma. Arch Ophthalmol. 2011;129(11):1416–21.
51. Aziz HA, Lasenna CE, Vigoda M, Fernandes C, Feuer W, Aziz-Sultan MA, et al. Retinoblastoma treatment burden and economic cost: impact of age at diagnosis and selection of primary therapy. Vol. 6, Clinical ophthalmology (Auckland, N.Z.). 2012. p. 1601–6.
Cómo citar
Gómez Vega, J. C., Ocampo-Navia, M. I., Botero-Trujillo, J. J. ., Fandiño-Hidalgo, R. E., & Puentes Vargas, J. C. (2021). Quimioterapia intra-arterial para el manejo del retinoblastoma. Universitas Medica, 62(4). https://doi.org/10.11144/Javeriana.umed62-4.quim
Sección
Artículos de revisión

Artículos más leídos del mismo autor/a